

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 02 STN pricing information for 2008 now available
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4 JAN 28 USPATFULL, USPATZ2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5 JAN 28 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREP reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra
NEWS 16 MAR 31 CA/Caplus and CASREACT patent number format for U.S. applications updated
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN Anavist, Version 1, to be discontinued

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 14:54:37 ON 08 APR 2008

```
=> file reg
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                    ENTRY      SESSION
FULL ESTIMATED COST                           0.21          0.21
```

FILE 'REGISTRY' ENTERED AT 14:55:07 ON 08 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 APR 2008 HIGHEST RN 1012704-12-9
DICTIONARY FILE UPDATES: 7 APR 2008 HIGHEST RN 1012704-12-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=>
Uploading C:\Program Files\Stnexp\Queries\10530499a.str
```




chain nodes :
12 13 15 16 17 18 19 20
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-17 2-12 3-16 8-18 12-13 12-15 18-19 19-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9
exact/norm bonds :
1-2 1-6 1-17 2-3 2-12 3-4 3-16 4-5 4-7 5-6 5-9 7-8 8-9 8-18 12-13
12-15 18-19 19-20
isolated ring systems :
containing 1 :

G1:C,N

G2:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 12:CLASS
13:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:Atom 20:CLASS

=> d 11
L1 HAS NO ANSWERS
L1 STR



G1 C,N
G2 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s 11 full
FULL SEARCH INITIATED 14:55:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 18247 TO ITERATE

100.0% PROCESSED 18247 ITERATIONS 158 ANSWERS
SEARCH TIME: 00.00.01

L2 158 SEA SSS FUL L1

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	178.36	178.57

FILE 'CAPLUS' ENTERED AT 14:55:32 ON 08 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Apr 2008 VOL 148 ISS 15
FILE LAST UPDATED: 7 Apr 2008 (20080407/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12 full

L3 9 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1123456 CAPLUS
DOCUMENT NUMBER: 145:454932
TITLE: Preparation of nitrogen-containing heterocyclic
compounds as antitumor agents
INVENTOR(S): Murakata, Chikara; Amishiro, Nobuyoshi; Atsumi,
Toshiyuki; Yamashita, Yoshinori; Takahashi, Takeshi;
Nakai, Ryuichiro; Tagaya, Hisashi; Takahashi, Hiroko;
Funahashi, Jun; Yamamoto, Junichiro; Fukuda, Yuichi
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 531pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006112479	A1	20061026	WO 2006-JP308224	20060419
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006237920	A1	20061026	AU 2006-237920	20060419
CA 2610446	A1	20061026	CA 2006-2610446	20060419
EP 1880993	A1	20080123	EP 2006-745456	20060419
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
KR 2008011199	A	20080131	KR 2007-726727 JP 2005-120953 WO 2006-JP308224	20071116 A 20050419 W 20060419
PRIORITY APPLN. INFO.:				

OTHER SOURCE(S): MARPAT 145:454932
GI



AB Nitrogen-containing heterocyclic compds. such as 7-(indol-2-yl)isoindolinone and 4-(indol-2-yl)-1,2-dihydro-1H-pyrrolo[3,4-c]pyridin-3-one derivs. [I; W = N, CH; X = CO, (un)substituted CH; R1 = Q; q1 = N, (un)substituted CH; Q2 = O, S, (un)substituted NH; R2, R3 R5, R6 = H, halo, NO2, HO, cyano, CO2H, each (un)substituted lower alkyl, cycloalkyl, aralkyl, lower

alkenyl, lower alkynyl, aryl, heterocyclyl, lower alkanoyl, lower alkoxy carbonyl, aroyl, heteroaroyl, or HO, S(O)mR18; m = an integer of 0-2; R18 = H, HO, each (un)substituted lower alkoxy, lower alkyl, cycloalkyl, aralkyl, lower alkenyl, aryl, heterocyclyl, or NH2] or pharmacol. acceptable salts thereof are prepared. These compds. are useful as protein kinase inhibitors, in particular fibroblast growth factor receptor (FGFR) inhibitors, Aurora kinase inhibitors, and FMS-like tyrosine kinase-3 (FLT-3) inhibitors, and thereby as antitumor agents for treatment of hematopoietic tumors, in particular leukemia, multiple myeloma, and lymphoma. Thus, reductive alkylation of 1-(2-hydroxyethyl)piperazine with 4-chloro-7-[1-(tert-butoxycarbonyl)-5-formylindol-2-yl]isoindolinone using sodium triacetoxymethoxyborohydride in a mixture of AcOH and MeCN followed by treatment with HCl/EtOAc gave 4-chloro-7-(1H-5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]indol-2-yl)isoindolinone dihydrochloride (II). II at 10 μ M inhibited $\geq 50\%$ human FGFR3 expressed in insect cells, human multiple myeloma KMS-11 cells, and human stomach cancer cells KATO-III.


IT 913385-43-0P, 4-Chloro-7-[[1H-5-[(pyridin-2-yl)methyl]amino]carbonyl]benzimidazol-2-yl]carbonyl]isoindolinone

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nitrogen-containing heterocyclic compds. as protein kinase inhibitors and antitumor agents)

RN 913385-43-0 CAPLUS

CN 1H-Benzimidazole-6-carboxamide, 2-[(7-chloro-2,3-dihydro-3-oxo-1H-isoindol-4-yl)carbonyl]-N-(2-pyridinylmethyl)- (CA INDEX NAME)



REFERENCE COUNT:

11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:665189 CAPLUS

DOCUMENT NUMBER: 145:327641

TITLE: Novel benzimidazole derivatives as selective CB2 inverse agonists

AUTHOR(S): Page, D.; Brochu, M.-C.; Yang, H.; Brown, W.; St-Onge, S.; Martin, E.; Salois, D.

CORPORATE SOURCE: Department of Chemistry, AstraZeneca R and D Montreal, Ville St-Laurent, QC, H4S 1Z9, Can.

SOURCE: Letters in Drug Design & Discovery (2006), 3(5), 298-303

CODEN: LDDDAW; ISSN: 1570-1808
PUBLISHER: Bentham Science Publishers Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The preparation and evaluation of a novel class of CB2 benzimidazole inverse agonists are reported. They showed binding affinities up to 0.7 nM towards CB2 with overall good selectivity over the CB1 receptor. They also reversed the effect of the cannabinoid agonist WIN55212-2 in competition assays showing K_i values up to 1.2 nM.


IT 474015-61-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(novel benzimidazole derivs. as selective CB2 inverse agonists)

RN 474015-61-7 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-(3-methylbutyl)- (CA INDEX NAME)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1117980 CAPLUS

DOCUMENT NUMBER: 144:16432

TITLE: Virtual Screening of Novel CB2 Ligands Using a Comparative Model of the Human Cannabinoid CB2 Receptor

AUTHOR(S): Salo, Outi M. H.; Raitio, Katri H.; Savinainen, Juha R.; Nevalainen, Tapio; Lahtela-Kakkonen, Maija; Laitinen, Jarmo T.; Jaervinen, Tomi; Poso, Antti

CORPORATE SOURCE: Department of Pharmaceutical Chemistry, University of Kuopio, Kuopio, FIN-70211, Finland

SOURCE: Journal of Medicinal Chemistry (2005), 48(23), 7166-7171

PUBLISHER: CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: American Chemical Society
Journal

LANGUAGE: English

AB To identify novel selective CB2 lead compds., a comparative model of the CB2 receptor was constructed using the high-resolution bovine rhodopsin X-ray structure as a template. The CB2 model was utilized both in building the database queries and in filtering the hit compds. by a docking and scoring method. In G-protein activation assays, 1-isoquinolyl[3-(trifluoromethyl)phenyl]methanone (40, NRB 04079) was found to act as a selective agonist at the human CB2 receptor.


IT 474016-55-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(virtual screening of novel CB2 ligands using CB2 receptor model)

RN 474016-55-2 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-[(2R)-1-methyl-2-piperidinyl]methyl- (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT:

112 THERE ARE 112 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:369276 CAPLUS
DOCUMENT NUMBER: 142:411658
TITLE: Preparation of 2-(aminoalkyl)-5-
benzimidazolecarboxamide derivatives as peptide
deformylase inhibitors
INVENTOR(S): Hjelmentrantz, Anders; Cali, Patrizia; Groth, Thomas;
Jensen, Christian Eeg; Naerum, Lars
PATENT ASSIGNEE(S): Arpida A/S, Den.
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037272	A1	20050428	WO 2004-DK679	20041008
WO 2005037272	A8	20050623		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, NZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1677785	A1	20060712	EP 2004-762898	20041008
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007509082	T	20070412	JP 2006-535947	20041008
US 20070066672	A1	20070322	US 2006-572415	20060317
PRIORITY APPLN. INFO.:			DK 2003-1553	A 20031022
			US 2003-513891P	P 20031023
			WO 2004-DK679	W 20041008

OTHER SOURCE(S): CASREACT 142:411658; MARPAT 142:411658
GI



AB The invention relates to benzimidazole compds. I [X is CONHOH, CO2H, OH or SH; R1 is alkyl, cycloalkyl, mercapto-, alkylthio-, hydroxy- or carboxyalkyl, etc., (un)substituted aryl or heteroaryl, or a side chain of a natural α -amino acid, with the proviso that R1 cannot be H or tert-butyl; R2 is alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, alkoxy, mercaptoalkyl, hydroxyalkyl, alkylthio, etc., (un)substituted aryl or heteroaryl; R3 is NHCHR4COR5, NR6R7, NHR7 or OR7, where R4 is H or a side chain of a natural α -amino acid, R5 is amino, hydroxy, alkoxy or alkylamino, and R6, R7 are independently heterocycloalkyl, aryl or heteroaryl] and their pharmaceutically-acceptable salts or esters which are peptide deformylase inhibitors useful in the treatment or prevention of infections and other diseases in which peptide deformylases are involved, especially in the treatment of bacterial and parasitic infections. Thus, peptidyl compound II was prepared by the solid-phase method and showed IC50 values 65.0 and 45.4 microM for inhibition of the enzyme from *E. coli* and *S. aureus*, resp.

IT 850487-92-2P 850487-94-4P 850488-02-7P


850488-04-9P 850488-66-3P 850488-68-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of (aminoalkyl)benzimidazolecarboxamide derivs. as peptide deformylase inhibitors)


RN 850487-92-2 CAPLUS

CN Glycine, N-[1-(1-cyclopropyl-2-[2-(4-hydroxyphenyl)-1-[(3-mercaptopro-1-oxopropyl)amino]ethyl]-1H-benzimidazol-5-yl]carbonyl-, methyl ester (CA INDEX NAME)



RN 850487-94-4 CAPLUS


CN Glycine, N-[1-(1-cyclohexylmethyl)-2-[2-(4-hydroxyphenyl)-1-[(3-mercaptopro-1-oxopropyl)amino]ethyl]-1H-benzimidazol-5-yl]carbonyl-, methyl ester (CA INDEX NAME)



RN 850488-02-7 CAPLUS


CN Butanoic acid, 4-[1-[1-cyclopropyl-5-[(2-methoxy-2-

oxoethyl)amino]carbonyl]-1H-benzimidazol-2-yl]-2-(4-hydroxyphenyl)ethyl]amino]-4-oxo- (CA INDEX NAME)




RN 850488-04-9 CAPLUS

CN Butanoic acid, 4-[1-[1-(cyclohexylmethyl)-5-[(2-methoxy-2-oxoethyl)amino]carbonyl]-1H-benzimidazol-2-yl]-2-(4-hydroxyphenyl)ethyl]amino]-4-oxo- (CA INDEX NAME)




RN 850488-66-3 CAPLUS

CN Glycine, N-[(1-cyclopropyl-2-[1-[(4-(hydroxyamino)-1,4-dioxobutyl]amino]-2-(4-hydroxyphenyl)ethyl]-1H-benzimidazol-5-yl]carbonyl]-, methyl ester (CA INDEX NAME)



RN 850488-68-5 CAPLUS

CN Glycine, N-[(1-(cyclohexylmethyl)-2-[1-[(4-(hydroxyamino)-1,4-dioxobutyl]amino]-2-(4-hydroxyphenyl)ethyl]-1H-benzimidazol-5-yl]carbonyl]-, methyl ester (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:354919 CAPLUS

DOCUMENT NUMBER: 140:375170

TITLE: Preparation of benzimidazolecarboxamides as CB2 receptor agonists for treating pain and other disorders

INVENTOR(S): Page, Daniel; Walpole, Christopher; Yang, Hua

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.

SOURCE: PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035548	A1	20040429	WO 2003-SE1604	20031015
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2501418	A1	20040429	CA 2003-2501418	20031015
AU 2003269775	A1	20040504	AU 2003-269775	20031015
EP 1554254	A1	20050720	EP 2003-751705	20031015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015320	A	20050816	BR 2003-15320	20031015
CN 1726194	A	20060125	CN 2003-80105921	20031015
JP 2006505568	T	20060216	JP 2004-545139	20031015
NZ 539079	A	20071130	NZ 2003-539079	20031015
US 20070105893	A1	20070510	US 2005-530499	20050406
ZA 2005002928	A	20060222	ZA 2005-2928	20050411
MX 2005PA03901	A	20050622	MX 2005-PA3901	20050412
NO 2005002182	A	20050503	NO 2005-2182	20050503
PRIORITY APPLN. INFO.:			SE 2002-3070	A 20021016
			WO 2003-SE1604	W 20031015

OTHER SOURCE(S): MARPAT 140:375170

GI



I



AB Benzimidazolecarboxamides (shown as I; variables defined below; e.g. II) as well as salts and pharmaceutical compns. including the compds. were prepared. These compds. are useful in therapy, in particular in the management of pain. For I: RF1 and RF2 = electron-withdrawing groups; Z = O and S; R1 = (un)substituted C1-10-alkyl, (un)substituted C2-10alkenyl, (un)substituted C2-10alkynyl, R3R4N-C1-6alkyl, R3R4NC(O)-C1-6alkyl, R3O-C1-6-alkyl, R3OC(O)-C1-6alkyl, R3C(O)-C1-6alkyl, R3C(O)NR3-C1-6alkyl, R3R4NSO2-C1-6alkyl, R3CSO2N(R4)-C1-6alkyl, R3R4NC(O)N(R5)-C1-6alkyl, R3R4NSO2N(R5)-C1-6alkyl, aryl-C1-6alkyl, aryl-C(O)-C1-6alkyl, heterocyclyl-C1-6alkyl, heterocyclyl-C(O)-C1-6alkyl, substituted aryl-C1-6alkyl, substituted aryl-C(O)-C1-6alkyl, substituted heterocyclyl-C1-6alkyl, substituted heterocyclyl-C(O)-C1-6alkyl, and C1-10hydrocarbylamino. R2 = (un)substituted C1-6alkyl, (un)substituted C2-6alkenyl, (un)substituted C2-6alkynyl, (un)substituted C3-6cycloalkyl, (un)substituted aryl, and (un)substituted C5-6heteroaryl; R3, R4 and R5 = H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, and a divalent C1-6group that together with another divalent C1-6group forms a portion of a ring; X is a C1-10 divalent group that separates groups connected thereto by one or two atoms; Ar is a C4-12 divalent aromatic group; and Y = CH and N; addnl. details are given in the claims. Methods of preparation are claimed and example preps. for .apprx.30 I and 39 intermediates are included. For example, II was prepared in 71% yield from 4-ethoxyphenylacetyl chloride and 3-amino-4-[(3-methylbutyl)amino]-N,N-bis(2,2,2-trifluoroethyl)benzamide, which was prepared in 99% yield by reduction of 4-[(3-methylbutyl)amino]-3-nitro-

N,N-bis(2,2,2-trifluoroethyl)benzamide, which was prepared in 99% yield from isoamylamine and 4-fluoro-3-nitro-N,N-bis(2,2,2-trifluoroethyl)benzamide, which was prepared in 66% yield from 4-fluoro-3-nitrobenzoic acid and bis(2,2,2-trifluoroethyl)amine. Dissociation consts. (Ki) for binding to CB1 and CB2 are tabulated for 36 examples of I; they show much stronger binding to CB2 than to CB1.

IT 683233-67-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of benzimidazolecarboxamides as CB2 receptor agonists for treating pain and other disorders)


RN 683233-67-2 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2R)-2-piperidinylmethyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (10:21) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-66-1
CMF C27 H30 F6 N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




IT 683233-41-2P 683233-42-3P 683233-43-4P
 683233-44-5P 683233-45-6P 683233-46-7P
 683233-47-8P 683233-48-9P 683233-49-0P
 683233-50-3P 683233-51-4P 683233-52-5P
 683233-53-6P 683233-54-7P 683233-55-8P
 683233-56-9P 683233-58-1P 683233-59-2P
 683233-60-5P 683233-61-6P 683233-62-7P
 683233-63-8P 683233-64-9P 683233-65-0P
 683233-66-1P 683233-68-3P 683233-69-4P
 683233-71-8P 683233-72-9P 683233-73-0P
 683233-74-1P 683233-75-2P 683233-76-3P
 683233-77-4P 683233-78-5P 683233-79-6P
 683233-80-9P 683233-81-0P 683233-82-1P
 683233-84-3P 683233-85-4P 683233-86-5P
 683233-87-6P 683233-88-7P 683233-89-8P
 683233-90-1P 683233-91-2P 683233-92-3P
 683233-93-4P 683233-94-5P 683233-95-6P
 683233-96-7P 683233-97-8P 683233-98-9P
 683233-99-0P 683234-00-6P 683234-01-7P
 683234-03-9P 683234-04-0P 683234-05-1P
 683234-06-2P 683234-07-3P 683234-08-4P
 683234-10-8P 683234-12-0P 683234-13-1P
 683234-14-2P 683234-15-3P 683234-16-4P
 683234-17-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzimidazolecarboxamides as CB2 receptor agonists for treating pain and other disorders)

RN 683233-41-2 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-(3-methylbutyl)-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683233-42-3 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-(3-methylbutyl)-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (10:3) (9CI)
 (CA INDEX NAME)

CM 1

CRN 683233-41-2
 CMF C26 H29 F6 N3 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 683233-43-4 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 1-(cyclopropylmethyl)-2-[(4-ethoxyphenyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 683233-44-5 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 1-(cyclopropylmethyl)-2-[(4-ethoxyphenyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-43-4

CMF C25 H25 F6 N3 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 683233-45-6 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 683233-46-7 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (10:9) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-45-6

CMF C28 H31 F6 N3 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 683233-47-8 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-(2-furanylmethyl)-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683233-48-9 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-(2-furanylmethyl)-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (5:2) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-47-8
CMF C26 H23 F6 N3 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 683233-49-0 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2S)-2-pyrrolidinylmethyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 683233-50-3 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2S)-2-pyrrolidinylmethyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (5:11) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-49-0
CMF C26 H28 F6 N4 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 683233-51-4 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2R)-2-pyrrolidinylmethyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 683233-52-5 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2R)-2-pyrrolidinylmethyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (5:1) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-51-4
 CMF C26 H28 F6 N4 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 683233-53-6 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-(4-pyridinylmethyl)-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683233-54-7 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-(4-pyridinylmethyl)-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-53-6
CMF C27 H24 F6 N4 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 683233-55-8 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[1-(4-ethoxyphenyl)ethyl]-1-(4-pyridinylmethyl)-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683233-56-9 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[1-(4-ethoxyphenyl)ethyl]-1-(4-pyridinylmethyl)-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (5:8) (9CI) (CA INDEX NAME)


CM 1

CRN 683233-55-8
CMF C28 H26 F6 N4 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 683233-58-1 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(tetrhydro-2H-pyran-4-yl)methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683233-59-2 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(tetrhydro-2H-pyran-4-yl)methyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (5:6) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-58-1
CMF C27 H29 F6 N3 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 683233-60-5 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2R)-tetrahydro-2-furanyl]methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 683233-61-6 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2R)-tetrahydro-2-furanyl]methyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (5:7) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-60-5
CMF C26 H27 F6 N3 O3

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 683233-62-7 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2S)-tetrahydro-2-furanyl]methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 683233-63-8 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2S)-tetrahydro-2-furanyl]methyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (5:7) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-62-7
CMF C26 H27 F6 N3 O3

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 683233-64-9 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-2-yl)methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683233-65-0 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(tetrahydro-2H-pyran-2-yl)methyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (5:8) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-64-9
CMF C27 H29 F6 N3 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 683233-66-1 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2R)-2-piperidinylmethyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 683233-68-3 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(5-ethoxy-2-pyridinyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 683233-69-4 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[(5-ethoxy-2-pyridinyl)methyl]-1-[(tetrahydro-2H-pyran-4-yl)methyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (5:8) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-68-3


CMF C26 H28 F6 N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 683233-71-8 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[(5-ethoxy-2-pyridinyl)methyl]-1-(3-methylbutyl)-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 683233-72-9 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[(5-ethoxy-2-pyridinyl)methyl]-1-(3-methylbutyl)-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (5:4) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-71-8

CMF C25 H28 F6 N4 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 683233-73-0 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2R)-1-methyl-2-pyrrolidinyl]methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 683233-74-1 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2R)-1-methyl-2-pyrrolidinylmethyl]-N,N-bis(2,2,2-trifluoroethyl)-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-73-0

CMF C27 H30 F6 N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 683233-75-2 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2R)-1-methyl-2-piperidinyl]methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 683233-76-3 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2R)-1-methyl-2-piperidinyl]methyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-75-2

CMF C28 H32 F6 N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 683233-77-4 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[(5-ethoxy-2-pyridinyl)methyl]-1-[(2R)-2-pyrrolidinylmethyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 683233-78-5 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, 2-[(5-ethoxy-2-pyridinyl)methyl]-1-[(2R)-2-pyrrolidinylmethyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (5:1) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-77-4

CMF C25 H27 F6 N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 683233-79-6 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[1-(4-ethoxyphenyl)ethyl]-1-[(2R)-2-pyrrolidinylmethyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 683233-80-9 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, 2-[1-(4-ethoxyphenyl)ethyl]-1-[(2R)-2-pyrrolidinylmethyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 683233-79-6

CMF C27 H30 F6 N4 O2

Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 683233-81-0 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(5-ethoxy-2-pyridinyl)methyl]-1-[(2R)-1-methyl-2-piperidinyl]methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 683233-82-1 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(5-ethoxy-2-pyridinyl)methyl]-1-[(2R)-1-methyl-2-piperidinyl]methyl]-N,N-bis(2,2,2-trifluoroethyl)-trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 683233-81-0
CMF C27 H31 F6 N5 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 683233-84-3 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(5-ethoxy-2-pyridinyl)methyl]-1-[(2R)-1-methyl-2-pyrrolidinyl]methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 683233-85-4 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(5-ethoxy-2-pyridinyl)methyl]-1-[(2R)-1-methyl-2-pyrrolidinyl]methyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 683233-84-3
CMF C26 H29 F6 N5 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 683233-86-5 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683233-87-6 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-(cyclobutylmethyl)-2-[(4-ethoxyphenyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (5:3) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-86-5
CMF C26 H27 F6 N3 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 683233-88-7 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 1-(cyclobutylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683233-89-8 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 1-(cyclobutylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-88-7
 CMF C25 H26 F6 N4 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 683233-90-1 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 1-(cyclopentylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683233-91-2 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 1-(cyclopentylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (10:11) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-90-1
 CMF C26 H28 F6 N4 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 683233-92-3 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2S)-2-piperidinylmethyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 683233-93-4 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2S)-2-piperidinylmethyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 683233-92-3
CMF C27 H30 F6 N4 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 683233-94-5 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(5-ethoxy-2-pyridinyl)methyl]-1-(3-furanyl methyl)-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683233-95-6 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(5-ethoxy-2-pyridinyl)methyl]-1-(3-furanyl methyl)-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (5:6) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-94-5
CMF C25 H22 F6 N4 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 683233-96-7 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(5-ethoxy-2-pyridinyl)methyl]-1-(3-thienylmethyl)-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683233-97-8 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(5-ethoxy-2-pyridinyl)methyl]-1-(3-thienylmethyl)-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (10:7) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-96-7
CMF C25 H22 F6 N4 O2 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 683233-98-9 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683233-99-0 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-(cyclohexylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (10:21) (9CI) (CA INDEX NAME)

CM 1

CRN 683233-98-9
CMF C27 H30 F6 N4 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 683234-00-6 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-(cyclohexylmethyl)-2-[(5-(1-methylethoxy)-2-pyridinyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683234-01-7 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-(cyclohexylmethyl)-2-[(5-(1-methylethoxy)-2-pyridinyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (5:3) (9CI) (CA INDEX NAME)

CM 1

CRN 683234-00-6
CMF C28 H32 F6 N4 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 683234-03-9 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(4-methyl-3-morpholinyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683234-04-0 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(4-methyl-3-morpholinyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (5:9) (9CI) (CA INDEX NAME)

CM 1

CRN 683234-03-9
CMF C27 H30 F6 N4 O3




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 683234-05-1 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 2-[(5-ethoxy-2-pyridinyl)methyl]-1-[(4-methyl-3-morpholinyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683234-06-2 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 2-[(5-ethoxy-2-pyridinyl)methyl]-1-[(4-methyl-3-morpholinyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 683234-05-1
 CMF C26 H29 F6 N5 O3




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 683234-07-3 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2S)-1-methyl-2-piperidinyl]methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 683234-08-4 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(2S)-1-methyl-2-piperidinyl]methyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (5:9) (9CI) (CA INDEX NAME)

CM 1

CRN 683234-07-3
 CMF C28 H32 F6 N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 02




RN 683234-10-8 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[(4-(1-methylethoxy)phenyl)methyl]-1-[(2R)-1-methyl-2-piperidinylmethyl]-N,N-bis(2,2,2-trifluoroethyl)-, trifluoroacetate (10:23) (9CI) (CA INDEX NAME)

CM 1

CRN 683234-09-5
CMF C29 H34 F6 N4 O2

Absolute stereochemistry.




CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 683234-12-0 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-[(1-methyl-2-piperidinyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683234-13-1 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[[4-(1-methylethoxy)phenyl]methyl]-1-[(1-methyl-2-piperidinyl)methyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 683234-14-2 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-(2-pyrrolidinylmethyl)-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 683234-15-3 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-1-(2-piperidinylmethyl)-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683234-16-4 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, 2-[(1-(4-ethoxyphenyl)ethyl)-1-(2-pyrrolidinylmethyl)-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 683234-17-5 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[(5-ethoxy-2-pyridinyl)methyl]-1-[(2S)-1-methyl-2-pyrrolidinylmethyl]-N,N-bis(2,2,2-trifluoroethyl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:511305 CAPLUS

DOCUMENT NUMBER: 139:85348

TITLE: Preparation of benzimidazoles and indoles as glucagon receptor antagonists/inverse agonists.

INVENTOR(S): Lau, Jesper; Christensen, Inge Thoger; Madsen, Peter; Behrens, Carsten

PATENT ASSIGNEE(S): Novo Nordisk A/s, Den.

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053938	A1	20030703	WO 2002-DK832	20021210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002347022	A1	20030709	AU 2002-347022	20021210
PRIORITY APPLN. INFO.:			DK 2001-1925	A 20011220
			WO 2002-DK832	W 20021210

OTHER SOURCE(S): MARPAT 139:85348
GI



AB Title compds. [I; A = HO₂C(CH₂)_m(CH₂)_n, tetrazolylalkyl; m = 0, 1; n = 0-3; m+n ≠ 0; R₁ = H, F, (CH₂)_oOR₂; o = 0, 1; R₂ = H, alkyl,

alkanoyl, aryl, aralkyl; X = N, CH; B = (substituted) Ph, naphthyl, azolyl, fluorenyl, norbornenyl; D = (CH₂)_p, CHPH(CH₂)_p, (CH₂)_pO; p = 0-4; E = (substituted) Ph, pyridinyl, azolyl, cycloalkenyl, etc.; with the exception of a specific compound, were prepared. Thus, title compound (II) and 26 addnl. I were prepared by solid phase synthesis using Fmoc-protected amino acids on Wang resin. Many I showed IC₅₀<1000 nM in a glucagon receptor binding assay.


IT 552839-46-0P 552839-53-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzimidazoles and indoles as glucagon receptor antagonists/inverse agonists)



RN 552839-46-0 CAPLUS

CN β -Alanine, N-[(2-[2-(2-methoxyphenyl)ethyl]-1-(4-phenylbutyl)-1H-benzimidazol-5-yl]carbonyl]- (CA INDEX NAME)



RN 552839-53-9 CAPLUS

CN β -Alanine, N-[(1-[(3,5-bis(trifluoromethyl)phenyl)methyl]-2-[(2-methoxyphenyl)methyl]-1H-benzimidazol-5-yl]carbonyl]- (CA INDEX NAME)



REFERENCE COUNT:



2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:832768 CAPLUS
 DOCUMENT NUMBER: 137:337892
 TITLE: Novel alkoxyarylbenzimidazoles as CB2 receptor
 agonists
 INVENTOR(S): Cheng, Yun-Xing; Tomaszewski, Miroslaw; Walpole,
 Christopher; Yang, Hua
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
 SOURCE: PCT Int. Appl., 112 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085866	A1	20021031	WO 2002-SE769	20020418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2444381	A1	20021031	CA 2002-2444381	20020418
AU 2002307586	A1	20021105	AU 2002-307586	20020418
EE 200300524	A	20040216	EE 2003-524	20020418
EP 1390350	A1	20040225	EP 2002-764120	20020418
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003003825	A2	20040301	HU 2003-3825	20020418
HU 2003003825	A3	20050628		
BR 2002008907	A	20040420	BR 2002-8907	20020418
CN 1503787	A	20040609	CN 2002-808577	20020418
JP 2004528334	T	20040916	JP 2002-583393	20020418
NZ 528403	A	20050527	NZ 2002-528403	20020418
NZ 538692	A	20060929	NZ 2002-538692	20020418
RU 2312864	C2	20071220	RU 2003-129638	20020418
ZA 2003007752	A	20050103	ZA 2003-7752	20031003
US 20040116465	A1	20040617	US 2003-474549	20031009
US 7030139	B2	20060418		
BG 108271	A	20041230	BG 2003-108271	20031014
NO 2003004665	A	20031210	NO 2003-4665	20031017
MX 2003PA09558	A	20040212	MX 2003-PA9558	20031017
US 20060135554	A1	20060622	US 2006-325124	20060104
PRIORITY APPLN. INFO.:			SE 2001-1387	A 20010420
			NZ 2002-528403	A1 20020418
			WO 2002-SE769	W 20020418
			US 2003-474549	A3 20031009

OTHER SOURCE(S): MARPAT 137:337892
 GI



AB Title compds. I [R1 = (un)substituted alkyl, alkenyl; R2 = alkyl, fluoroalkyl, cycloalkyl; R3 = (un)substituted H2NCONH, HCONH, HO2CNH, H2NCSNH, HSO2NH, H2NSO2, H2NCH2, H2NCS, H2NCO, NH2, acyl; X = (un)substituted CH2, NH, CO, CH2CH2, CH:CH, O, S, S(O), SO2; Y = CH, N; Ar = (un)substituted aryl] were prepared as CB2 receptor agonists in the management of pain. Thus, 4,3-F(O2N)C6H3CONH2 was treated with H2NCH2CH2CO2Et followed by reduction of the nitro group and cyclization with 4-EtOC6H4CH2COCl to give the benzimidazole II, formed by transesterification during chromatog. II had Ki for human CB2 receptor binding of 142 nM.


IT 474015-09-3P 474015-20-8P 474015-39-9P
 474015-48-0P 474016-36-9P 474016-41-6P
 474016-46-1P 474016-51-8P 474016-56-3P
 474016-61-0P 474016-67-6P 474017-17-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of novel alkoxyarylbenzimidazoles as CB2 receptor agonists)
 RN 474015-09-3 CAPLUS
 CN 1H-Benzimidazole-1-propanoic acid, 5-[(diethylamino)carbonyl]-2-[(4-ethoxyphenyl)methyl]-, methyl ester, trifluoroacetate (5:9) (9CI) (CA INDEX NAME)

CM 1

CRN 474015-08-2
 CMF C25 H31 N3 O4



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 474015-20-8 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-[2-(acetyl methylamino)ethyl]-2-[(4-ethoxyphenyl)methyl]-, N,N-diethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 474015-19-5
CMF C26 H34 N4 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 474015-39-9 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-[2-(dimethylamino)-1-methylethyl]-2-[(4-ethoxyphenyl)methyl]-, N,N-diethyl-, trifluoroacetate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 474015-38-8
CMF C26 H36 N4 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 474015-48-0 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-[(cyclopropylmethyl)-2-[(6-ethoxy-3-pyridinyl)methyl]-N,N-diethyl- (CA INDEX NAME)



RN 474016-36-9 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-(3-thienylmethyl)-, trifluoroacetate (10:17) (9CI) (CA INDEX NAME)

CM 1

CRN 474016-35-8
CMF C26 H29 N3 O2 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 474016-41-6 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-[(2R)-2-pyrrolidinylmethyl]-, trifluoroacetate (5:11) (9CI) (CA INDEX NAME)

CM 1

CRN 474016-40-5
CMF C26 H34 N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 474016-46-1 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-[(2S)-tetrahydro-2-furanyl]methyl-, trifluoroacetate (2:5) (9CI) (CA INDEX NAME)

CM 1

CRN 474016-45-0
CMF C26 H33 N3 03

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 Q2




RN 474016-51-8 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-[(2R)-1-methyl-2-pyrrolidinyl]methyl-, trifluoroacetate (5:12) (9CI)
(CA INDEX NAME)

CM 1

CRN 474016-50-7
CMF C27 H36 N4 02

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 474016-56-3 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-[(2R)-1-methyl-2-piperidinyl]methyl-, trifluoroacetate (10:21) (9CI)
(CA INDEX NAME)

CM 1

CRN 474016-55-2
CMF C28 H38 N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 474016-61-0 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-[(2S)-1-methyl-2-piperidinyl]methyl-, trifluoroacetate (10:21) (9CI)
(CA INDEX NAME)

CM 1

CRN 474016-60-9

CMF C28 H38 N4 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 474016-67-6 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)hydroxymethyl]-N,N-diethyl-1-(3-methylbutyl)-, trifluoroacetate (5:6) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 474016-66-5

CMF C26 H35 N3 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 474017-17-9 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-[(5-nitro-2-thienyl)methyl]- (CA INDEX NAME)



IT 474015-15-1P 474015-62-8P 474015-69-5P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)
(preparation of novel alkoxyarylbenzimidazoles as CB2 receptor agonists)
RN 474015-15-1 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-(2-aminoethyl)-2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-, trifluoroacetate (5:14) (9CI) (CA INDEX NAME)

CM 1

CRN 474015-14-0
CMF C23 H30 N4 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 474015-62-8 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-(3-methylbutyl)-, trifluoroacetate (10:17) (9CI) (CA INDEX NAME)

CM 1

CRN 474015-61-7
 CMF C26 H35 N3 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 474015-69-5 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 2-(4-ethoxybenzoyl)-N,N-diethyl-1-(3-methylbutyl)- (CA INDEX NAME)



IT 474014-92-1P 474014-98-7P 474015-03-7P
 474015-25-3P 474015-29-7P 474015-37-7P
 474015-44-6P 474015-52-6P 474015-56-0P
 474015-66-2P 474015-71-9P 474015-73-1P
 474016-14-3P 474017-37-3P 474017-41-9P
 474017-45-3P 474017-49-7P 474017-52-2P
 474017-58-8P 474017-65-7P 474017-86-2P
 474017-92-0P 474017-99-7P 474018-02-5P

474018-06-9P 474018-09-2P 474018-13-8P
474018-15-0P 474018-19-4P 474018-22-9P
474018-24-1P 474018-27-4P 474018-31-0P
474018-34-3P 474018-66-1P 474018-69-4P
474019-56-2P 474019-59-5P 474020-70-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRP (Preparation); USES (Uses)
(preparation of novel alkoxyarylbenzimidazoles as CB2 receptor agonists)


RN 474014-92-1 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, N,N-diethyl-2-[(4-methoxyphenyl)methyl]-1-[2-(4-morpholinyl)ethyl]-, tris(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 474014-91-0

CMF C26 H34 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 474014-98-7 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-(2-methoxyethyl)-, trifluoroacetate (5:1) (9CI) (CA INDEX NAME)

CM 1

CRN 474014-97-6

CMF C24 H31 N3 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 474015-03-7 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-[2-(acetylamino)ethyl]-2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-, trifluoroacetate (10:21) (9CI) (CA INDEX NAME)

CM 1

CRN 474015-02-6
CMF C25 H32 N4 O3



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 474015-25-3 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-methyl-, trifluoroacetate (10:21) (9CI) (CA INDEX NAME)

CM 1

CRN 474015-24-2
CMF C22 H27 N3 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 474015-29-7 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-(2-phenylethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 474015-28-6
CMF C29 H33 N3 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 474015-37-7 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-[2-(1-piperidinyl)ethyl]-, trifluoroacetate (5:13) (9CI) (CA INDEX NAME)

CM 1

CRN 474015-36-6
CMF C28 H38 N4 O2



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 474015-44-6 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-(cyclopropylmethyl)-2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-, trifluoroacetate (10:19) (9CI) (CA INDEX NAME)

CM 1

CRN 474015-43-5
CMF C25 H31 N3 O2




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 474015-52-6 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-[2-(dimethylamino)ethyl]-2-[(4-

ethoxyphenyl)ethyl]-N,N-diethyl- (CA INDEX NAME)



BN 474015-56-0 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 1-(cyclopropylmethyl)-2-[2-(4-ethoxyphenyl)ethyl]-N,N-diethyl- (CA INDEX NAME)




RN 474015-66-2 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-(4-pyridinylmethyl)-, trifluoroacetate (10:21) (9CI) (CA INDEX NAME)

CM 1

CRN 474015-65-1

CME C27 H30 N4 O2



CM 2


CRN 76-05-1

CME C2 H F3 O2




RN 474015-71-9 CAPLUS

CN 1H-Benzimidazole-5-carbothioamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-(3-methylbutyl)- (CA INDEX NAME)



RN 474015-73-1 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, N-cyclohexyl-1-(cyclopropylmethyl)-2-[(4-ethoxyphenyl)methyl]-N-methyl-, hydrochloride (5:11) (CA INDEX NAME)



●11/5 HCl


RN 474016-14-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-6-carboxamide, 3-(cyclopropylmethyl)-2-[(4-ethoxyphenyl)methyl]-N,N-diethyl- (CA INDEX NAME)




RN 474017-37-3 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 1-[2-(dimethylamino)ethyl]-2-[(4-ethoxyphenyl)methyl]-N,N-diethyl- (CA INDEX NAME)




RN 474017-41-9 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 474017-45-3 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-cyclopropyl-2-[(4-ethoxyphenyl)methyl]-N,N-diethyl- (CA INDEX NAME)




RN 474017-49-7 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-(cyclopropylmethyl)-2-[(4-ethoxyphenyl)methyl]-N,N-bis(1-methylethyl)- (CA INDEX NAME)




RN 474017-52-2 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 474017-58-8 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-cyclobutyl-1-(cyclopropylmethyl)-2-[(4-ethoxyphenyl)methyl]-N-methyl- (CA INDEX NAME)




RN 474017-65-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-6-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-3-(3-methylbutyl)- (CA INDEX NAME)




RN 474017-86-2 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-(cyclopropylmethyl)-2-[(5-ethoxy-2-pyridinyl)methyl]-N-ethyl- (CA INDEX NAME)



RN 474017-92-0 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-(cyclopropylmethyl)-2-[(4-ethoxyphenyl)methyl]-N-ethyl- (CA INDEX NAME)




RN 474017-99-7 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-[(2-chloro-4-thiazolyl)methyl]-2-[(4-ethoxyphenyl)methyl]-N,N-diethyl- (CA INDEX NAME)




RN 474018-02-5 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-(4-thiazolylmethyl)- (CA INDEX NAME)




RN 474018-06-9 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-(2-quinolinylmethyl)- (CA INDEX NAME)




RN 474018-09-2 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)




RN 474018-13-8 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-[2-(dimethylamino)ethyl]-N,N-diethyl-2-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 474018-15-0 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N,N-diethyl-1-[2-(4-morpholinyl)ethyl]-2-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



RN 474018-19-4 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-1-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 474018-22-9 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N,N-diethyl-1-[2-(1-piperidinyl)ethyl]-2-[[4-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 474018-24-1 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[(1E)-2-(4-ethoxyphenyl)ethenyl]-N,N-diethyl-1-[(1-ethyl-2-pyrrolidinyl)methyl]- (CA INDEX NAME)

Double bond geometry as shown.




RN 474018-27-4 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, N,N-diethyl-1-[(1-ethyl-2-pyrrolidinyl)methyl]-2-[(4-(trifluoromethoxy)phenyl)methyl]- (CA INDEX NAME)



RN 474018-31-0 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, 1-(cyclopropylmethyl)-2-[(4-ethoxyphenyl)methyl]-N-ethyl-N-(phenylmethyl)- (CA INDEX NAME)



RN 474018-34-3 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, 1-(cyclopropylmethyl)-2-[(4-ethoxyphenyl)methyl]-N-[(2R)-tetrahydro-2-furanyl]methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 474018-66-1 CAPLUS

CN 1H-Benzimidazole-5-carbothioamide, 1-(cyclopropylmethyl)-2-[(4-ethoxyphenyl)methyl]-N-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)




RN 474018-69-4 CAPLUS

CN 1H-Benzimidazole-5-carbothioamide, 1-(cyclopropylmethyl)-N-[2-(dimethylamino)ethyl]-2-[(4-ethoxyphenyl)methyl]-N-ethyl- (CA INDEX NAME)



RN 474019-56-2 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, 1-[2-(dimethylamino)ethyl]-2-[(4-ethoxyphenyl)ethyl]-N,N-diethyl-, hydrochloride (5:14) (CA INDEX NAME)



●14/5 HCl

RN 474019-59-5 CAPLUS


CN 1H-Benzimidazole-5-carboxamide, 1-(cyclopropylmethyl)-2-[(4-ethoxyphenyl)ethyl]-N,N-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 474020-70-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-6-carboxamide, 3-(cyclopropylmethyl)-2-[(4-ethoxyphenyl)methyl]-, N,N-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:87826 CAPLUS
 DOCUMENT NUMBER: 124:218061
 TITLE: Manufacture of printed circuit board
 INVENTOR(S): Ono, Takao; Akaike, Shinichi
 PATENT ASSIGNEE(S): Tamura Kaken Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07307552	A	19951121	JP 1994-119657	19940510
PRIORITY APPLN. INFO.:			JP 1994-119657	19940510
OTHER SOURCE(S):	MARPAT	124:218061		
GI				




AB To form a circuit wiring pattern having through holes a Cu-coated substrate is etched after forming an etching resist film on through holes and in their periphery using a solution containing ≥ 1 benzimidazole compound I (X1 = halo, NH2, lower dialkylamino, OH, lower alkoxy, CN, Ac, benzoyl, NH2CO, CHO, COOH, lower alkoxy carbonyl, NO2; Y1 = C1-20 (branched) alkyl; n = 1-4), II (X2, Y2 (sic) = halo, NH2, lower dialkylamino, OH, lower alkoxy, CN, Ac, benzoyl, NH2CO, CHO, COOH, lower alkoxy carbonyl, NO2; Y2 = C1-7 (branched) alkyl; n, p = 0-4; m = 1-10), and/or its salt. The resist film may be heated or oxidized before etching.

IT 152937-37-6

RL: TEM (Technical or engineered material use); USES (Uses)
 (etching resist films containing benzimidazole derivative for patterning of printed circuit boards)


RN 152937-37-6 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[2-(2,4-dihydroxyphenyl)ethyl]- (9CI)
 (CA INDEX NAME)



L3 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1994:137286 CAPLUS
 DOCUMENT NUMBER: 120:137286
 TITLE: Heat-resistant protective agents for printed circuit boards
 INVENTOR(S): Sasahara, Yasumichi; Shibata, Seiji
 PATENT ASSIGNEE(S): Tamura Kaken Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05186888	A	19930727	JP 1992-157615	19920617
JP 3112744	B2	20001127		
PRIORITY APPLN. INFO.:			JP 1991-232877	A1 19910912
OTHER SOURCE(S):	MARPAT	120:137286		
GI				




AB The title agents contain I (X = C1-7 alkyl, halo, NH₂, OH, CN, AcO, BzO, CO₂H, NO₂, low alkoxy, di-(low)alkylamino, carbamoyl, formyl, low alkoxycarbonyl). Soaking an etched Cu plate in an aqueous solution containing tartaric acid and 2-(8-phenyloctyl)benzimidazole gave a plate with good heat and moisture resistance and solderability.

IT 152937-37-6

RL: USES (Uses)
 (aqueous solns. of, as protective agents, for printed circuit boards, for solderability)

RN 152937-37-6 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[2-(2,4-dihydroxyphenyl)ethyl]- (9CI)
 (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	50.01	228.58
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.20	-7.20

STN INTERNATIONAL LOGOFF AT 14:56:49 ON 08 APR 2008